A PYMNTS Company

Australia: Pfizer clears antitrust hurdle in Hospira acquisition

By  |  August 13, 2015

Pfizer announced that the Australian Competition and Consumer Commission has approved the company’s pending acquisition of Hospira and found no need for remedies.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    “We are pleased to have achieved another significant milestone for Pfizer’s pending acquisition of Hospira with the ACCC’s approval of the transaction,” said Ian Read, chairman and chief executive officer, Pfizer. “We continue to work cooperatively with the regulatory agencies to obtain the requisite approvals, and continue to expect the transaction to close in the second half of 2015.”

    Completion of the transaction remains subject to the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, governmental and regulatory approvals in certain other jurisdictions and other usual and customary closing conditions.

    Full content: RTT News

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.